Tenecteplase Thrombolysis for Stroke up to 24 Hours After Onset With Perfusion Imaging Selection: The CHABLIS-T II Randomized Clinical Trial.

2025-02
Stroke 56(2)
- Xin Cheng
- Lan Hong
- Longting Lin
- Leonid Churilov
- Yifeng Ling
- Nan Yang
- Jianliang Fu
- Guozhi Lu
- Yunhua Yue
- Jin Zhang
- Feng Wang
- Ziran Wang
- Yanxin Zhao
- Xiaoyu Zhou
- Zhaolong Peng
- Danhong Wu
- Liandong Zhao
- Qijin Zhai
- Xiaofei Yu
- Qi Fang
- Xiangzhong Shao
- Ying Tang
- Diwen Zhang
- Yu Geng
- Yue Zhang
- Bosheng Fan
- Bing Zhang
- Congguo Yin
- Yangmei Chen
- Yiran Zhang
- Xinyu Liu
- Siyuan Li
- Lumeng Yang
- Mark Parsons
- Qiang Dong

PubMed: 39744861
DOI: 10.1161/strokeaha.124.048375

Study Design

Type: Randomized Controlled Trial (RCT)
Sample size: n = 123
Population: Chinese patients with acute ischemic stroke due to large/medium vessel occlusion within 4.5 to 24 hours from last known well, with favorable penumbral profile
Methods: Randomized 1:1 to 0.25 mg/kg tenecteplase or best medical treatment, with imaging selection; primary outcome assessed at 24-48 hours
Blinding: Open-label
Duration: 90 days
Funding: Unclear

Large Human Trial

Background

Whether it is effective and safe to extend the time window of intravenous thrombolysis up to 24 hours after the last known well is unknown. We aimed to determine the efficacy and safety of tenecteplase in Chinese patients with acute ischemic stroke due to large/medium vessel occlusion within an extended time window.

Methods

Patients with ischemic stroke presenting 4.5 to 24 hours from the last known well, with a favorable penumbral profile and an associated large/medium vessel occlusion, were randomized 1:1 to either 0.25 mg/kg tenecteplase or the best medical treatment. A favorable penumbral profile was defined as a hypoperfusion lesion volume to infarct core volume ratio >1.2, with an absolute volume difference >10 mL, and an ischemic core volume <70 mL. The primary outcome was the achievement of major reperfusion without symptomatic intracranial hemorrhage within 24 to 48 hours post-randomization. Major reperfusion was defined as the restoration of blood flow of >50% of the involved ischemic territory. Secondary outcomes included recanalization, infarct growth, major neurological improvements, change in the National Institutes of Health Stroke Scale score, hemorrhagic transformation within 24 to 48 hours, systemic bleeding at discharge, and modified Rankin Scale (score 0-1, score 0-2, score 5-6, and modified Rankin Scale distribution) at 90 days. The comparison of the primary outcome between groups was conducted using modified Poisson regression with a log-link function and robust error variance, adjusted for time from the last known well to randomization, the site of vessel occlusion, and planned endovascular treatment.

Results

Among 224 enrolled patients, 111 were assigned to receive tenecteplase and 113 to receive the best medical treatment (including 23% [n=26] of participants who received intravenous tissue-type plasminogen activator). The mean (SD) age of the tenecteplase group and the best medical treatment group was 64.2 (10.4) and 63.6 (11.0) years old, with 72.1% (n=80) and 70.8% (n=80) male enrolled, respectively. A proportion of 54.9% (n=123) of patients were transferred to the catheter room for preplanned endovascular treatment. The primary outcome occurred in 33.3% (n=37) of the tenecteplase group versus 10.8% (n=12) in the best medical treatment group (adjusted relative risk, 3.0 [95% CI, 1.6-5.7]; P=0.001). Tenecteplase significantly increased the recanalization rate compared with the best medical treatment (35.8% [n=39] versus 14.3% [n=16], adjusted relative risk, 2.5 [95% CI, 1.4-4.4]; P=0.002). There were no significant differences in clinical efficacy outcomes or rates of hemorrhagic transformation between the groups.

Conclusions

Administered at a dose of 0.25 mg/kg intravenously, tenecteplase increased reperfusion without symptomatic intracranial hemorrhage in patients with ischemic stroke selected by imaging in late-time window treatment but did not change clinical outcomes at 90 days.

Registration

URL: https://www.clinicaltrials.gov; Unique identifier: NCT04516993.